Anavex Life Sciences Corp. reports developments as a clinical-stage biopharmaceutical company focused on central nervous system disorders, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome, and other neurodevelopmental, neurodegenerative, and rare diseases. Company news frequently centers on blarcamesine, its orally administered lead candidate, along with precision-medicine analyses using genomic and biomarker data.
Recurring updates include clinical and preclinical data presentations, scientific findings related to autophagy, synaptic dysfunction, SIGMAR1 biology, and disease mechanisms, as well as regulatory communications with the FDA and EMA. News also covers financial results, healthcare conference participation, board composition, executive leadership changes, and other corporate governance matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Anavex Life Sciences Corp. (Nasdaq: AVXL), a biopharmaceutical company focused on treatments for neurodegenerative disorders, announced that its CEO, Christopher U. Missling, PhD, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference. This event is scheduled for May 2, 2023, at 9:30 am ET, held at NASDAQ World Headquarters in New York City. Anavex's lead candidate, ANAVEX®2-73 (blarcamesine), has shown promising results in multiple clinical trials for conditions like Alzheimer’s and Parkinson’s diseases. The company also develops ANAVEX®3-71, targeting key receptors to potentially modify Alzheimer's disease. Anavex is committed to advancing therapeutics that address significant unmet medical needs in the CNS space.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced that its CEO, Christopher U Missling, PhD, will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 8:00 AM ET. The presentation can be accessed via a live audio webcast on the company's website, with an archived version available later the same day.
Anavex is focused on developing therapeutics for neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Rett syndrome. Its leading drug candidate, ANAVEX®2-73 (blarcamesine), has completed several clinical trials showing potential benefits in restoring cellular homeostasis. The company's commitment includes extensive research and development efforts, supported by grants such as one from the Michael J. Fox Foundation for Parkinson's Research.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced the successful preliminary results from the 48-week Phase 2 study of ANAVEX®2-73 (blarcamesine) for Parkinson's disease dementia. The study achieved both primary and secondary objectives, showing consistent improvements in clinical symptoms throughout the trial. ANAVEX®2-73 was generally safe and well-tolerated. The company plans to move forward with a pivotal trial for Parkinson's disease following these results. Additionally, patient-requested treatment has continued beyond the study through a compassionate use program. The Michael J. Fox Foundation awarded a grant for further research on ANAVEX®2-73.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced the appointment of Kun Jin, Ph.D., as Vice President, Head of Biostatistics. With over 27 years at the FDA, Dr. Jin is expected to enhance Anavex’s clinical development efforts, particularly in addressing neurodegenerative diseases like Alzheimer's and Parkinson's. CEO Christopher U Missling emphasized Dr. Jin's experience in maximizing shareholder value and advancing key programs. Anavex is dedicated to developing therapeutics for various CNS disorders, with significant advancements in their lead drug candidate, ANAVEX®2-73, which has shown promise in Phase 2 trials for Alzheimer's and Parkinson's disease.
Anavex Life Sciences Corp. (Nasdaq: AVXL) reported financial results for the fiscal quarter ending December 31, 2022. The company focuses on developing therapeutics for neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease. Anavex highlighted promising results from the Phase 2b/3 Alzheimer's trial of ANAVEX®2-73, which achieved significant improvements in cognition and function. Financially, Anavex reported a net loss of $13.0 million, or $0.17 per share, up from a loss of $10.9 million in the same quarter last year. Cash reserves stood at $143.6 million, down from $149.2 million, while R&D expenses increased to $12.1 million.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced the successful enrollment of 92 patients in the Phase 2/3 study of ANAVEX®2-73 (blarcamesine) for Rett syndrome, surpassing its target. The study, known as EXCELLENCE, is focused on pediatric patients aged 5 to 17 and measures the safety, tolerability, and efficacy of the treatment. Topline results are anticipated in the second half of 2023. ANAVEX®2-73 has previously received Fast Track, Rare Pediatric Disease, and Orphan Drug designations from the FDA. This trial follows successful Phase 2 and Phase 3 studies in adults with Rett syndrome, demonstrating the company's commitment to developing therapeutics for neurodevelopmental disorders.